« Return to News | Clinical Intelligence

Neurelis completes dosing in study of intranasal diazepam

Wednesday, April 20, 2011 12:05 PM

Neurelis has completed the subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.

Through the collaboration with the University of Minnesota and James Cloyd, PharmD, Neurelis has partnered with clinical researchers regarding the nasal delivery of benzodiazepines.  Results from this important study are expected in June.

"Neurelis has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures.  These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits," stated David Hale, chairman of Neurelis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.